Navigation Links
Phase III Data on Safinamide in Parkinson’s Disease Presented,at American Academy of Neurology 59th Annual Meeting

s

Some of the statements in this press release are forward looking. Such statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of Merck Serono S.A. and affiliates to be materially different from those expected or anticipated in the forward-looking statements. Forward-looking statements are based on Merck Serono’s current expectations and assumptions, which may be affected by a number of factors, including those discussed in this press release and more fully described in Serono’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on February 28, 2006. These factors include any failure or delay in Merck Serono’s ability to develop new products, any failure to receive anticipated regulatory approvals, any problems in commercializing current products as a result of competition or other factors, our ability to obtain reimbursement coverage for our products, the outcome of any government investigations and litigation. Merck Serono is providing this information as of the date of this press release, and has no responsibility to update the forward-looking statements contained in this press release to reflect events or circumstances occurring after the date of this press release.

###

About Merck Serono S.A.

Merck Serono S.A. is a global biotechnology leader, with sales in over 90 countries. The Company is the world leader in reproductive health, with Gonal-f®, Luveris® and Ovidrel®/Ovitrelle®. It has strong market positions in neurology, with Rebif®, as well as in metabolism and growth, with Saizen®, Serostim® and Zorbtive™. The Company has recently entered the psoriasis area with Raptiva®. Merck Serono's research programs are focused on growing these businesses and on establishing new therapeutic areas
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:7/28/2014)... , July 28, 2014  Isis Pharmaceuticals, Inc. (NASDAQ: ... Second Quarter 2014 Financial Results and Highlights Conference CallWhen:Monday, ... PTWhere: www.isispharm.com How:Live on the Internet. Simply log ... to participate during the live event, a replay of ... at www.isispharm.com . ABOUT ISIS PHARMACEUTICALS, ...
(Date:7/28/2014)... -- CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) ... 2014 financial results on Monday, August 4, 2014, after ... announcement, members of the management team will host a ... a general corporate update at 4:30 p.m. EDT (1:30 ... as follows: Monday, August 4 1:30 ...
(Date:7/25/2014)... 25, 2014  In today,s marketplace, launching multiple products ... - as is managing a portfolio of products in ... possible - or even preferable - to pool resources ... you combine resources and activities, and what marketing and ... are just a few of the dilemmas facing pharmaceutical ...
Breaking Medicine Technology:Webcast Alert: Isis Pharmaceuticals' Second Quarter 2014 Financial Results Conference Call 2CTI BioPharma to Report Second Quarter 2014 Financial Results on August 4, 2014 2Using Promotional Efficiency to Support Multiple Products and Indications in the Pharmaceutical Marketplace 2
... , SAN DIEGO, Nov. 18 Rules-Based ... biomarker alliance and services agreement with Covance Inc. (NYSE: ... with a powerful combination of biomarker technologies and services for ... will use RBM as its exclusive third-party provider of multiplexed ...
... , NASHVILLE, Tenn., Nov. 17 Emdeon (NYSE: ... cycle management solutions, today announced that it will participate in the ... 1 to 2, 2009 in New York. , The "fireside chat", ... time on Tuesday, December 1, 2009. A live audio webcast ...
Cached Medicine Technology:Rules-Based Medicine Forms Biomarker Alliance With Covance Inc. 2Rules-Based Medicine Forms Biomarker Alliance With Covance Inc. 3
(Date:7/28/2014)... (PRWEB) July 28, 2014 The ... the majority of professionals engaged in the field ... the Transplantation and Immunology Research Network ... and immunology research. As modern organ transplantation continues ... network that could provide more opportunities for physicians, ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 At some point ... situation where they’re forced to contact the authorities. Distinguishing ... difficult than it initially seems. , Not every dangerous situation ... get stolen, a person get mugged, or a bank get ... obvious, leading onlookers to be more passive than they otherwise ...
(Date:7/28/2014)... University of Texas Health Science Center at San Antonio, the ... of pills that cures 9 of 10 hepatitis C patients. ... or without ribavirin, cured 93 percent of patients in 12 ... study published today in The Lancet . , ... Lawitz, M.D., clinical professor in the School of Medicine at ...
(Date:7/28/2014)... HealthDay Reporter MONDAY, July 28, ... have a slightly increased risk of potentially fatal blood ... report. Doctors have previously suspected that babies born ... of deep vein thrombosis and pulmonary embolism, two serious ... researchers noted in background information. This new study ...
(Date:7/28/2014)... 2014A two-step decision tree analysis, incorporating Donabedian,s model, ... the many available quality standards, guidelines, recommendations and ... international quality standards for radiation therapy, according to ... of Practical Radiation Oncology (PRO), the ... for Radiation Oncology (ASTRO). , Guidelines, recommendations and ...
Breaking Medicine News(10 mins):Health News:American Society of Transplantation (AST) Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding 2Health News:American Society of Transplantation (AST) Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding 3Health News:Take Action To Protect Your Fellow Citizens 2Health News:Take Action To Protect Your Fellow Citizens 3Health News:New pill regimens published in The Lancet cure hardest-to-treat hepatitis C patients 2Health News:Preemies May Have Higher Risk of Blood Clots, Even as Adults 2Health News:Preemies May Have Higher Risk of Blood Clots, Even as Adults 3Health News:Two-step decision tree analysis helps inform updates of RT best practices, quality standards 2Health News:Two-step decision tree analysis helps inform updates of RT best practices, quality standards 3
... Consumer Watchdog sent a letter to Senator ... expressing their profound disappointment that consumer advocates had ... the Massachusetts senator to formulate health care reform ... recent national polls showing the public overwhelming opposed ...
... Results To Offer New Insights on How Well Asthma ... The American Lung Association of New England (ALANE) has ... offer an online survey and corresponding report that will ... being controlled and encourage them to discuss the results ...
... ROCKVILLE, Md., Feb. 20 /PRNewswire-Asia/ -- Synutra,International, ... a leading infant formula,company in China, and ... products,for infants, children and adults, today issued ... permit numbers in a published list of ...
... eFoodSafety.com, Inc., (OTC Bulletin Board: EFSF) an emerging ... aesthetics, dermatology, environmental and nutraceutical products, outlined its ... 30, 2010 during its regularly scheduled monthly investor ... eFoodSafety.com intends to increase revenues by improving the ...
... Many people seek answers to questions of motivation and ... by Justin Honaman employs lessons learned in his career ... an effort to help others direct their energies and ... chapters of "Make It Happen" that personal branding is ...
... the world,s largest autism science and advocacy organization, is teaming up ... series "Wow! Wow! Wubbzy!" - to promote World Autism Awareness Day ... autism as a worldwide health crisis. , ... New ...
Cached Medicine News:Health News:Consumer Watchdog to U.S. Senate: Don't Leave Consumers Out of Health Reform Debate, Public Opposes Mandatory Purchases of Private Insurance & Supports Opening Medicare to Everyone 2Health News:American Lung Association of New England Launches Online Asthma Control Test 2Health News:American Lung Association of New England Launches Online Asthma Control Test 3Health News:American Lung Association of New England Launches Online Asthma Control Test 4Health News:Synutra Issues Statement Regarding Market Rumors on Revocation of its Production Certification 2Health News:Synutra Issues Statement Regarding Market Rumors on Revocation of its Production Certification 3Health News:eFoodSafety.com Provides Revenue Guidance for FY 2010 2Health News:eFoodSafety.com Provides Revenue Guidance for FY 2010 3Health News:Business Strategist Applies Corporate Experience to Self-Help: 'Make It Happen' 2Health News:Autism Speaks and 'Wow! Wow! Wubbzy!' Team Up to Shine a Spotlight on World Autism Awareness Day 2Health News:Autism Speaks and 'Wow! Wow! Wubbzy!' Team Up to Shine a Spotlight on World Autism Awareness Day 3Health News:Autism Speaks and 'Wow! Wow! Wubbzy!' Team Up to Shine a Spotlight on World Autism Awareness Day 4
... The Finnpipette Digital Multichannel, ... even lighter work of routine ... all these advanced features: Soft-touch ... micro volume pipetting (0.5-10ul models), ...
... Unique to the Medtronic Hall, the aortic and ... In the aortic position, the disc opens to ... valve opens to 70 to minimize regurgitation. Designed ... the surgeon to align the leading edge of ...
... Pipettor , , The Shortyavailable with both ... how our face-to-face relationship with the scientific community ... make pipetting easier and more effective., Shorter ... Gets you closer to the working area ...
The Biopette E has a comfortable, ergonomic design. Fully motorized piston drive. Virtually eliminates pipetting forces. User-friendly operator interface. Simple, precise volume setting. Rechargelabl...
Medicine Products: